Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  DeCensi, Andrea ^a,b   Thorat, Mangesh A ^b,c   Bonanni, Bernardo ^d   Smith, Samuel G ^b,e   Cuzick, Jack ^b  

^a GALLIERA HOSPITAL   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aspirin; Biomarkers; Breast cancer; Cancer; Drug repurposing; Preventive therapy; SERMs

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; AWARENESS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG REPOSITIONING; DRUG SAFETY; HEALTH CARE DISPARITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEOPLASM; ONCOLOGIST; PATIENT HARM; PHASE 3 CLINICAL TRIAL (TOPIC); PREJUDICE; PREVENTION STUDY; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH PRIORITY; RISK BENEFIT ANALYSIS; STRATEGIC PLANNING;

EID: 84960463645     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.595     Document Type: Article

References (76)

1. Cuzick J, Sestak I and Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data Lancet 381(9880) 1827-1834 doi: 10.1016/S0140-6736(13)60140-3 pmid: 23639488 pmcid: 3671272
2. Cuzick J, Sestak I and Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial Lancet 383(9922) 1041-1048 doi: 10.1016/S0140-6736(13)62292-8
3. Goss PE, Ingle JN and Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women N Engl J Med 364(25) 2381-2391 doi: 10.1056/NEJMoa1103507 pmid: 21639806
4. Visvanathan K, Chlebowski RT and Hurley P et al (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction J Clin Oncol 27(19) 3235-3258 doi: 10.1200/JCO.2008.20.5179 pmid: 19470930 pmcid: 2716943
5. Chlebowski RT, Col N and Winer EP et al (2002) American society of clinical oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition J Clin Oncol 20(15) 3328-3343 doi: 10.1200/JCO.2002.06.029 pmid: 12149307
6. Visvanathan K, Hurley P and Bantug E et al (2013) Use of pharmacologic interventions for breast cancer risk reduction: American society of clinical oncology clinical practice guideline J Clin Oncol 31(23) 2942-2962 doi: 10.1200/JCO.2013.49.3122 pmid: 23835710
7. National institute for health and clinical excellence (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer CG164: national institute for health and clinical excellence 2013 Report No.: CG164 Contract No.: CG164
8. Ropka ME, Keim J and Philbrick JT (2010) Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis J Clin Oncol 28(18) 3090-3095 doi: 10.1200/JCO.2009.27.8077 pmid: 20458026 pmcid: 2903338
9. Donnelly LS, Evans DG and Wiseman J et al (2014) Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic Br J Cancer 110(7) 1681-1687 doi: 10.1038/bjc.2014.109 pmid: 24594998 pmcid: 3974072
10. Melnikow J, Paterniti D and Azari R et al (2005) Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction Cancer 103(10) 1996-2005 doi: 10.1002/cncr.20981 pmid: 15825209
11. Brentnall A, Evans D and Cuzick J (2013) Value of phenotypic and single-nucleotide polymorphism panel markers in predicting the risk of breast cancer J Genet Syndr Gene Ther 4(202) 2 doi: 10.4172/2157-7412.1000202
12. Warwick J, Birke H and Stone J et al (2014) Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the international breast cancer intervention study I Breast Cancer Res 16(5) 451 doi: 10.1186/s13058-014-0451-5 pmid: 25292294 pmcid: 4303130
13. Brentnall AR, Evans DG and Cuzick J (2014) Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK Br J Cancer 110(3) 827-828 doi: 10.1038/bjc.2013.747 pmid: 24448363 pmcid: 3915120
14. Freedman AN, Graubard BI and Rao SR et al (2003) Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention J Natl Cancer Inst 95(7) 526-532 doi: 10.1093/jnci/95.7.526 pmid: 12671020
15. Waters EA, McNeel TS and Stevens WM et al (2012) Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 Breast Cancer Res Treat 134(2) 875-880 doi: 10.1007/s10549-012-2089-2 pmid: 22622807 pmcid: 3771085
16. Waters EA, Cronin KA and Graubard BI et al (2010) Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women Cancer Epidemiol Biomarkers Prev 19(2) 443-446 doi: 10.1158/1055-9965.EPI-09-0930 pmid: 20142242 pmcid: 3038785
17. Smith SG, Sestak I and Forster A et al Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis Submitted
18. Kaplan CP, Haas JS and Perez-Stable EJ et al (2005) Factors affecting breast cancer risk reduction practices among California physicians Prev Med 41(1) 7-15 doi: 10.1016/j.ypmed.2004.09.041 pmid: 15916987
19. Malek K, Fink AK and Thwin SS et al (2004) The relationship among physicians' specialty, perceptions of the risks and benefits of adjuvant tamoxifen therapy, and its recommendation in older patients with breast cancer Med Care 42(7) 700-706 doi: 10.1097/01.mlr.0000129905.64831.5d pmid: 15213495
20. Taylor R and Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump Ann Fam Med 3(3) 242-247 doi: 10.1370/afm.284 pmid: 15928228 pmcid: 1466885
21. Kinney AY, Richards C and Vernon SW et al (1998) The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial Prev Med 27(5 Pt 1) 713-719 doi: 10.1006/pmed.1998.0349 pmid: 9808803
22. Rondanina G, Puntoni M and Severi G et al (2008) Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users J Clin Oncol 26(9) 1537-1543 doi: 10.1200/JCO.2007.13.6739 pmid: 18349406
23. Cuzick J, Sestak I and Thorat MA (2015) Impact of preventive therapy on the risk of breast cancer among women with benign breast disease Breast doi: 10.1016/j.breast.2015.07.013 pmid: 26255741
24. Blaha P, Dubsky P and Fitzal F et al (2009) Breast cancer chemoprevention-a vision not yet realized Eur J Cancer Care (Engl) 18(5) 438-446 doi: 10.1111/j.1365-2354.2008.00951.x
25. Reeder JG and Vogel VG (2007) Breast cancer risk management Clin Breast Cancer 7(11) 833-840 doi: 10.3816/CBC.2007.n.047
26. Vogel VG (2007) Chemoprevention strategies 2006 Curr Treat Options Oncol 8(1) 74-88 doi: 10.1007/s11864-007-0019-z pmid: 17634835
27. Ravdin PM (2010) The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention Cancer Prev Res 3(6) 686-688 doi: 10.1158/1940-6207.CAPR-10-0100
28. Narod SA (2015) Tamoxifen chemoprevention-end of the road? JAMA Oncol doi: 10.1001/jamaoncol.2015.2247
29. Cameron DA (2014) Breast cancer chemoprevention: little progress in practice? Lancet 383(9922) 1018-1020 doi: 10.1016/S0140-6736(13)62555-6
30. Port ER, Montgomery LL and Heerdt AS et al (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention Ann Surg Oncol 8(7) 580-585 doi: 10.1007/s10434-001-0580-9 pmid: 11508619
31. Fagerlin A, Zikmund-Fisher BJ and Nair V et al (2010) Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid Breast Cancer Res Treat 119(3) 613-620 doi: 10.1007/s10549-009-0618-4
32. Kaplan CP, Kim SE and Wong ST et al (2012) Willingness to use tamoxifen to prevent breast cancer among diverse women Breast Cancer Res Treat 133(1) 357-366 doi: 10.1007/s10549-012-1960-5 pmid: 22315131 pmcid: 4039196
33. Heisey R, Pimlott N and Clemons M et al (2006) Women's views on chemoprevention of breast cancer: qualitative study Can Fam Physician 52 624-625 pmcid: 1531726
34. Paterniti DA, Melnikow J and Nuovo J et al (2005) "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction Ethn Dis 15(3) 365-372 pmid: 16108294
35. Waters EA, Weinstein ND and Colditz GA et al (2009) Explanations for side effect aversion in preventive medical treatment decisions Health Psychol 28(2) 201-209 doi: 10.1037/a0013608 pmid: 19290712 pmcid: 2657933
36. Bober SL, Hoke LA and Duda RB et al (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors J Clin Oncol 22(24) 4951-4957 doi: 10.1200/JCO.2004.05.192 pmid: 15598980
37. Herberman RB, Pearce HL and Lippman SM et al (2006) Cancer chemoprevention and cancer preventive vaccines - a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need Cancer Res 66(24) 11540-11549 doi: 10.1158/0008-5472.CAN-06-4122 pmid: 17158189
38. Veronesi U, Maisonneuve P and Decensi A (2007) Tamoxifen: an enduring star J Natl Cancer Inst 99(4) 258-260 doi: 10.1093/jnci/djk072 pmid: 17312297
39. Tanne JH (2006) Court awards claimant $13.5m in rofecoxib lawsuit
40. Cuzick J, Sestak I and Cawthorn S et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial Lancet Oncol 16(1) 67-75 doi: 10.1016/S1470-2045(14)71171-4
41. Cuzick J, Wickerham L and Powles T (2015) Letter to editor re: tamoxifen chemoprevention - end of the road? JAMA Oncol (submitted)
42. Cuzick J, Thorat MA and Andriole G et al (2014) Prevention and early detection of prostate cancer Lancet Oncol 15(11) e484-e492 doi: 10.1016/S1470-2045(14)70211-6 pmid: 25281467 pmcid: 4203149
43. Thompson IM, Goodman PJ and Tangen CM et al (2003) The influence of finasteride on the development of prostate cancer N Engl J Med 349(3) 215-224 doi: 10.1056/NEJMoa030660 pmid: 12824459
44. Andriole GL, Bostwick DG and Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer N Engl J Med 362(13) 1192-1202 doi: 10.1056/NEJMoa0908127 pmid: 20357281
45. Robinson D, Garmo H and Bill-Axelson A et al (2013) Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study BMJ 346 f3406 doi: 10.1136/bmj. f3406
46. Thompson IM, Jr., Goodman PJ and Tangen CM et al (2013) Long-term survival of participants in the prostate cancer prevention trial N Engl J Med 369(7) 603-610 doi: 10.1056/NEJMoa1215932 pmid: 23944298 pmcid: 4141537
47. Schmitz-Drager BJ, Schoffski O and Marberger M et al (2014) Risk adapted chemoprevention for prostate cancer: an option? Recent results Cancer Res 202 79-91 doi: 10.1007/978-3-642-45195-9-10
48. Cuzick J, Thorat MA and Bosetti C et al (2015) Ann Oncol 26(1) 47-57 doi: 10.1093/annonc/mdu225 pmcid: 4269341
49. Grimshaw E (2014) Aspirin Sales Go Through the City's Roof Western Daily Press (Bristol, UK) (http://www.westerndailypress. co.uk/Aspirin-sales-city-s-roof/story-22709471-detail/story.html)
50. Off-patent Drugs Bill 2014-15, (2014) The House of Commons, United Kingdom
51. DeCensi A, (ed) (2011) Discussion on: exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3-a randomized placebo-controlled clinical trial ASCO Annual Meeting
52. Cuzick J, Warwick J and Pinney E et al (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study J Natl Cancer Inst 103(9) 744-752 doi: 10.1093/jnci/djr079 pmid: 21483019
53. Thorat MA and Cuzick J (2013) Role of aspirin in cancer prevention Curr Oncol Rep 15(6) 533-540 doi: 10.1007/s11912-013-0351-3 pmid: 24114189
54. Thorat MA and Cuzick J (2015) Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population Eur J Epidemiol 30(1) 5-18 doi: 10.1007/s10654-014-9971-7
55. Mabert K, Cojoc M and Peitzsch C et al (2014) Cancer biomarker discovery: current status and future perspectives Int J Radiat Biol 90(8) 659-677 doi: 10.3109/09553002.2014.892229 pmid: 24524284
56. Puhan MA, Yu T and Stegeman I et al (2015) Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer BMC Med 13 250 doi: 10.1186/s12916-015-0493-2 pmid: 26423305 pmcid: 4589917
57. Wald NJ and Law MR (2003) A strategy to reduce cardiovascular disease by more than 80% BMJ 326(7404) 1419 doi: 10.1136/bmj.326.7404.1419 pmid: 12829553 pmcid: 162259
58. Early breast cancer trialists' collaborative group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351(9114) 1451-1467 doi: 10.1016/S0140-6736(97)11423-4 pmid: 9605801
59. Decensi A, Bonanni B and Guerrieri-Gonzaga A et al (1998) Biologic activity of tamoxifen at low doses in healthy women J Natl Cancer Inst 90(19) 1461-1467 DOI: 10.1093/jnci/90.19.1461 PMID: 9776411
60. Decensi A, Robertson C and Viale G et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers J Natl Cancer Inst 95(11) 779-790 DOI: 10.1093/jnci/95.11.779 PMID: 12783932
61. DeCensi A, Bonanni B and Maisonneuve P et al (2013) A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study Ann Oncol 24(11) 2753-2760 DOI: 10.1093/annonc/mdt244 PMID: 23864098
62. Guerrieri-Gonzaga A, Lazzeroni M and Botteri E et al (2013) Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Ann Oncol 24(7) 1859-1866 DOI: 10.1093/annonc/mdt113 PMID: 23532115
63. Trial of low dose tamoxifen in women with breast intraepithelial neoplasia (TAM-01) [database on the Internet] U.S. national institutes of health (2011) [cited 16/09/2015]. Available from: http://clinicaltrials.gov/ct2/show/NCT01357772
64. Low-dose tamoxifen citrate in reducing breast cancer risk in radiation-induced cancer survivors (LDTam) [database on the Internet] U.S. national institutes of health (2010) [cited 16/09/2015]. Available from: http://clinicaltrials.gov/ct2/show/NCT01196936
65. Decensi A, Dunn BK and Puntoni M et al (2012) Exemestane for breast cancer prevention: a critical shift? Cancer Discov 2(1) 25-40 DOI: 10.1158/2159-8290.CD-11-0248 PMID: 22585166 PMCID: 3354700
66. Evans TR, Di Salle E and Ornati G et al (1992) Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women Cancer Res 52(21) 5933-5939 PMID: 1394219
67. Johannessen DC, Engan T and Di Salle E et al (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study Clin Cancer Res 3(7) 1101-1108 PMID: 9815789
68. Lazzeroni M and DeCensi A Alternate dosing schedules for cancer chemopreventive agents Sem Oncol doi: 10.1053/j.seminoncol. 2015.09.014
69. Lung cancer prevention (PDQ(R)): health professional version (2002) PDQ Cancer information summaries Bethesda (MD)
70. Omenn GS, Goodman GE and Thornquist MD et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334(18) 1150-1155 DOI: 10.1056/NEJM199605023341802 PMID: 8602180
71. Hennekens CH, Buring JE and Manson JE et al (1996) Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease N Engl J Med 334(18) 1145-1149 DOI: 10.1056/NEJM199605023 341801 PMID: 8602179
72. The alpha-tocopherol, beta carotene cancer prevention study group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers N Engl J Med 330(15) 1029-1035 DOI: 10.1056/NEJM199404143301501 PMID: 8127329
73. Lee IM, Cook NR and Manson JE et al (1999) Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the women's health study J Natl Cancer Inst 91(24) 2102-2106 DOI: 10.1093/jnci/91.24.2102 PMID: 10601381
74. Lee IM, Cook NR and Gaziano JM et al (2005) Vitamin E in the primary prevention of cardiovascular disease and cancer: the women's health study: a randomized controlled trial JAMA 294(1) 56-65 DOI: 10.1001/jama.294.1.56 PMID: 15998891
75. Lonn E, Bosch J and Yusuf S et al (2005) Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial JAMA 293(11) 1338-1347 DOI: 10.1001/jama.293.11.1338 PMID: 15769967
76. Heart protection study collaborative G (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360(9326) 23-33 DOI: 10.1016/S0140-6736(02)09328-5 PMID: 12114037